Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma

Maura Massimino, Rosalba Miceli, Felice Giangaspero, Luna Boschetti, Piergiorgio Modena, Manila Antonelli, Paolo Ferroli, Daniele Bertin, Emilia Pecori, Laura Grazia Valentini, Veronica Biassoni, Maria Luisa Garre', Elisabetta Schiavello, Iacopo Sardi, Armando Cama, E. Viscardi, Giovanni Scarzello, Silvia Scoccianti, Maurizio Mascarin, Lucia QuagliettaGiuseppe Cinalli, Barbara Diletto, Lorenzo Genitori, Paola Peretta, Anna Mussano, Annamaria Buccoliero, Giuseppina Calareso, Salvina Barra, Angela Mastronuzzi, Carlo Giussani, Carlo Efisio Marras, R. Balter, P. Bertolini, E. Giombelli, Milena La Spina, Francesca Romana Buttarelli, Bianca Pollo, Lorenza Gandola

Research output: Contribution to journalArticlepeer-review


Background This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III). Methods WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4 courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1-4 VEC courses, second-look surgery, and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1-3 years with grade II tumors could receive 6 VEC courses alone. Results From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y; males, 100). Follow-up was a median of 67 months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multivariable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable. Conclusions In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters emerging in this series will be the object of future correlatives and reports.

Original languageEnglish
Pages (from-to)1451-1460
Number of pages10
Issue number10
Publication statusPublished - Oct 1 2016


  • boost
  • ependymoma
  • grade
  • prognosis
  • surgery

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma'. Together they form a unique fingerprint.

Cite this